Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors

胸腺癌 医学 胸腺瘤 贝伐单抗 内科学 养生 卡铂 化疗 肿瘤科 紫杉醇 血液学 耐火材料(行星科学) 顺铂 胃肠病学 外科 物理 天体生物学
作者
Changlu Wang,Liang Gao,Chang-Xing Lyu,Qin Zhang,Wenhui Zeng,Wentao Fang,Lei Zhu,Xiaolong Fu
出处
期刊:Medical Oncology [Springer Science+Business Media]
卷期号:39 (2) 被引量:2
标识
DOI:10.1007/s12032-021-01620-9
摘要

There are no optimal regimens for advanced thymic epithelial tumors (TETs) when frontline chemotherapy fails. In this study, we aimed to assess the activity of Bevacizumab in combination with a routine chemotherapeutic regimen. Patients with advanced TETs who had failed after previous chemotherapy were enrolled in this study. Paclitaxel (160 mg/m2) and cisplatin (70 mg/m2) or carboplatin (area under the curve, 6) plus Bevacizumab (7.5 mg/kg) were intravenously injected on day 1.The treatment was repeated every 3 weeks until the disease progressed or intolerable toxicities occurred. Between March 2018 and August 2020, a total of 49 patients (21 thymoma and 28 thymic carcinoma) received the new treatment. There were 28 men and 21 women with a median age of 50 years (range: 21-73 years). The median number of cycles was 3 (range: 1-6) per patient. The objective response rate (ORR) for all patients was 43% (21/49). The ORRs for thymoma and thymic carcinoma were 24% and 57%, respectively. The median progression-free survival for thymoma and thymic carcinoma was 6 and 8 months, respectively. Hematological toxicities were the main side effects. Paclitaxel and platinum plus Bevacizumab showed promising effects in refractory or relapsed advanced TETs without severe toxicity. Even when applied as salvage therapy, this regimen resulted in a better ORR than frontline chemotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沉眠猫猫虫完成签到,获得积分10
刚刚
1秒前
lili完成签到,获得积分10
1秒前
热情的果汁应助wu采纳,获得10
1秒前
帅气白梦完成签到 ,获得积分10
2秒前
笔花医镜发布了新的文献求助10
2秒前
3秒前
4秒前
5秒前
的的的墨完成签到,获得积分10
5秒前
Lucas应助memedaaaah采纳,获得10
5秒前
cherry完成签到,获得积分10
6秒前
Cherish完成签到,获得积分10
7秒前
田様应助linkman采纳,获得10
7秒前
8秒前
YHDing完成签到,获得积分10
8秒前
lan完成签到,获得积分10
8秒前
8秒前
9秒前
yyyfff应助关关采纳,获得10
9秒前
ED应助李治稳采纳,获得10
9秒前
orixero应助小李采纳,获得10
10秒前
小马甲应助阿冰采纳,获得10
10秒前
安详曼安关注了科研通微信公众号
10秒前
10秒前
小蘑菇应助火星上香菇采纳,获得10
12秒前
andrewyu发布了新的文献求助10
12秒前
12秒前
Owen应助沟通亿心采纳,获得10
12秒前
夜猫放羊完成签到,获得积分10
12秒前
思源应助老实乌冬面采纳,获得10
12秒前
shiyi发布了新的文献求助10
13秒前
13秒前
LY完成签到,获得积分10
13秒前
13秒前
14秒前
14秒前
15秒前
15秒前
15秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974779
求助须知:如何正确求助?哪些是违规求助? 3519193
关于积分的说明 11197417
捐赠科研通 3255311
什么是DOI,文献DOI怎么找? 1797760
邀请新用户注册赠送积分活动 877150
科研通“疑难数据库(出版商)”最低求助积分说明 806187